Key result
High-dose ceftriaxone plus amikacin cures native mitral valve E. coli endocarditis without surgery.
Why the study?
Escherichia coli is a rare cause of infectious endocarditis.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
May support medical management of rare E. coli native mitral endocarditis; hypothesis-generating and should not yet change practice.
Escherichia coli is a rare cause of infectious endocarditis. We report a clinical case of E. coli endocarditis of a native mitral valve in a young 26-year-old woman with a recurrent urinary tract infection who had a high fever for one week despite probabilistic treatment with amoxcillin-clavulanic acid 3 g per day. The patient was successfully treated with antibiotics and recovered without surgery.
No takes yet. Share an insight, caveat, or question.
Benaissa et al. (2021) conducted a case report in Infective endocarditis of a native mitral valve caused by Escherichia coli (n=1). Ceftriaxone and amikacin was evaluated on Clinical recovery and microbiological cure without surgery. Intravenous ceftriaxone (4 g/day for 6 weeks) and amikacin (160 mg/day for 10 days) resolved fever within 72 hours and cured native mitral valve E. coli endocarditis without surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: